Consumer data showed that 11% of UK adults are already current or former GLP-1 users, and their nutritional needs are “shifting dramatically”. Appetite reduction, taste changes and digestive sensitivity are driving users toward higher-protein, nutrient-dense, smaller-portion foods, said Vypr, and these are needs that are said to align closely with broader health trends in UK grocery.
The data comes as a new GLP-1 pill was launched on 6th July 2026, with the National Pharmacy Association anticipating a surge in patients starting weight-loss treatment.
Vypr found that despite a rise in GLP-1 users, explicit GLP-1 branding remains a “commercial risk”. It found that only 16% of non-users said they would consider buying a product labelled as ‘GLP-1-friendly’, even if it supported weight management. A further 42% were neutral, which Vypr said signalled “indifference rather than rejection”.
The consumer insight firm said that high-protein ready meals, nutrient-dense snack bars, portion-controlled meal kits and gentler-textured products can all serve GLP-1 users while appealing to the wider health-conscious market.
Brands should reformulate to take advantage of growing customer base
The Consumer Horizon Report from Vypr highlighted a “significant credibility challenge” as 54% of UK adults said they distrust generic GLP-1 treatments, with distrust rising sharply among consumers over 65. While 25-34-year-olds were the most trusting age group, 39% still expressed distrust, and Vypr said that any food brand that leans too heavily into GLP-1 terminology risks inheriting this scepticism.
Among GLP-1 users, demand for food specifically for their needs is strong, and 70% said they would be more likely to buy food created especially for GLP-1 users. Nearly two-thirds (65%) would pay a premium for the products (mostly around 10% higher) and those aged 25-34 have the highest willingness to spend and the strongest trust in GLP-1-adjacent products.
Sentiment toward GLP-1 treatments was “notably polarised”: 35% of responses were positive (citing weight loss, reduced cravings and improved health markers) while 51% were negative (nausea, digestive issues, fatigue and taste distortion).
Ben Davies, founder of Vypr, commented: “GLP-1 users’ needs for high protein, nutrient density, clean ingredients and smaller portions are already driving mainstream category innovation. Marks & Spencer is leading the way with its range of healthy meals to appeal to this audience, which will grow massively as more people take up the weight-loss medication.
“GLP-1 is emerging as a category-shaping force in UK grocery. Brands don’t need to badge products as GLP-1-friendly. They just need to formulate smartly to take advantage of this growing customer base.”
